Charnwood Molecular is delighted to announce the Board-level appointment of Dr. Mark Chadwick to the new post of Chief Commercial Officer. Mark joins us from Arcinova, where he and his team significantly expanded the customer base over a 5-year period, before the recent acquisition of Arcinova by Quotient Sciences. Prior to that, he gained extensive experience of building both discovery and development businesses, most notably at BioFocus (now part of Charles River) and Excelsyn. He also spent 5 years as CEO of Physiomics, a listed oncology in silico modelling company.
Mark commented, “It’s a privilege and an honour to be invited to lead the next phase in Charnwood’s commercial development. I’m very much looking forward to engaging with the team and particularly our customers, to help deliver the first step towards life changing medicines for patients.”
Steve Allin, CEO of Charnwood Molecular added: “Mark joins us at an exciting time, as we begin to deliver our vision of becoming the provider of choice for drug discovery and development projects. Marks commercial acumen, experience and leadership as we begin to add new service lines, and undertake more complex integrated projects whilst operating from a new, world-class facility in 2021, will be invaluable in realising our strategic plan and in developing deep and meaningful collaborative partnerships with our global client base.”
